This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine.
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.
European Food Safety Authority (EFSA) has issued a new report from its Task Force on the Shiga toxin-producing E. coli (STEC) outbreak in Germany and France. The Task Force has now concluded that one lot of fenugreek seeds imported from Egypt and used to produce sprouts is the most likely common link between the two outbreaks. EFSA continues to advise consumers not to grow sprouts for their own consumption and not to eat sprouts or sprouted seeds unless they have been cooked thoroughly.
In the context of the ongoing outbreak of Shiga toxin-producing E. coli (STEC) that affects by now citizens from 13 EU member states, it is crucial not only to align the efforts regarding investigation and control of the outbreak but also to share knowledge among practitioners across Europe on the patho-physiological and clinical characteristics of infection caused by this unusual epidemic strain, and review patient management options.
Today, the German authorities published a press release on the current Shiga toxin-producing E.coli outbreak. In their joint statement they recommended in particular to abstain from eating raw sprouts.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.